Familial hypercholesterolaemia (FH) is an inherited autosomal codominant disorder caused by many different mutations in the low-density lipoprotein receptor (LDLR) gene. The one described most frequently in patients with FH from England, arises from a G--+A transition at the first nucleotide of codon 80, resulting in the substitution of lysine for glutamic acid at residue 80 of the mature protein, FH E80K.
circulating LDL cholesterol levels often accompanied by the presence of tendon xanthomata and coronary heart disease. I More than 300 different mutations of the LDLR gene have been characterized world-wide," 4 and a database of over 400 mutations is now available on a Web site (http://www.ucl.ac. uk/fh).
It is well known that there is considerable variation both in the severity of the disease in FH patients and in their response to cholesterollowering medication.' Therefore, the ability to identify the specific mutation responsible for FH is of value because it allows comparisons to be made between any individuals that have been shown to carry the same mutation. The mutation observed most frequently in the UK is FH E80K. It results from a single base change, G~A, in the first nucleotide of codon 80 of the LDL receptor gene, and has been described in patients attending lipid clinics in London and Manchester. ' To date, FH E80K has been identified by DNA analysis, involving hybridization with allele-specific oligonucleotide probes. However, this technique is extremely labour intensive and is not well-suited for the rapid processing of large numbers of samples. Furthermore, it is prone to give erroneous results if hybridization conditions are not strictly adhered to. In this report, we describe a modification of the polymerase chain reaction (PCR) known as PCR-mediated sitedirected mutagenesis," H that simplifies the detection of this point mutation. It is based upon the selective creation, by means of the PCR, of an artificial Tal! I restriction site in the normal, but not in the mutant allele, by the use of DNA sequence-modifying oligonucleotide primers.
In the present report, we have used this simple method to scan for the mutation in 410 patients with a clinical diagnosis of FH, attending lipid clinics in England, Scotland and Wales. This is founded on the premise that although there is no common FH mutation in the UK, regional overrepresentation of specific mutations, such as E80K in Manchester and R329X in Hampshire') does occur, and may be most evident in localities with stable populations. DNA from individuals identified as possible hcterozygotes for FH E80K, was further analysed, first to confirm E80K by sequencing and, secondly, in order to deduce the intragenic haplotype associated with the mutation and to identify a microsatellite marker D 19S394, which flanks the LDL receptor gene on chromosome 19 10 Although polymorphic microsatellite repeats flanking the Familial hypercholesterolaemia mutation 227 LDLR gene have not been used previously in the study of FH, their development both for family cosegregation studies and for linkage disequilibrium studies has been reported') and details of their characteristic typing and utility have been discussed." The objectives of this study were twofold. First, using the rapid screening method, to gain further insight regarding the incidence, manifestation and response to treatment of FH in individuals carrying this particular mutation. Secondly, using the results of the haplotype and microsatellite marker analysis, to determine whether FH E80K identified within individuals in different areas of Britain, arose from the same common ancestor. primers so that sequencing may be performed without further purification). These enzymes were then inactivated by heating at 80 GC for IS min. Sequencing was then performed in both directions using primers SP S9 or SP 60 according to the manufacturer's instructions. Genescan": procedure Two microlitres of each PCR product was mixed with O,SIlL of the internal size standard Genescan ROX 2S00 (Applied Biosysterns, Warrington, UK) and 2·0 ilL of loading buffer (Dextran Blue at a final concentration of 30 mg/ml, in a 1:5 (v/v) mixture of 50 mmol/L EDTA pH 8'0/deionized formamide). Samples were denatured at 95°C for 3 min and snap-chilled on ice and then subjected to electrophoresis on a 6% denaturing gel. The size of the PCR product was determined by reference to an internal standard. The programme calculates the size of any ROX-Iabelled peak using a local Southern method and uses these sizes to estimate the allele sizes of the PCR product.P Intra-laboratory precision was achieved by adjacent track or co-run on the same track of previously sized alleles. Genotyper version 1.1, was used to analyse and process the data and present it in a graphical format.
MATERIALS AND METHODS

Subjects
Haplotype analysis
Statistical analyses
Differences in total and LDL cholesterol concentrations before and after drug therapy were tested by one way analysis of variance.
Statistical significance was considered to be at the 0·05 level.
RESULTS
Explanation of mutagenic PCR
The principle of introducing the Taq I restriction site into codon 80 of the LDL receptor gene is illustrated in Fig. I . Amplification by the PCR generates a product 69 bp long. The upstream oligonucleotide primer contains a T instead of an A, one nucleotide from the 3' end. Consequently, DNA, amplified by the PCR, will contain a T rather than an A at this position, which is two base pairs upstream from the mutant site. In DNA in which the codon 80 mutation is absent, this generates a PCR product with the sequence TCGA, outlined in bold in Fig. I , which is the recognition sequence for Taq I. However, in mutant DNA containing A instead of G at the first nucleotide of codon 80, the generated sequence is TCAA, which is not recognized by Taq I. Consequently, following digestion of amplified DNA by Taq I, DNA containing the normal allele is cut into two fragments of 40 and 29 bp, whereas DNA containing the mutant allele is not. Following polyacrylamide gel electrophoresis, the presence of a single fragment 69 bp long therefore indicates DNA homozygous for the FH E80K mutation, the presence of two fragments of 40 and 29 bp, indicates, DNA homozygous for wild-type DNA, and the presence of three bands of 69,40 and 29 bp, indicates DNA heterozygous for FH E80K (Fig. 2) . A typical polyacrylamide gel run is shown in Fig. 3 .
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Analysis of patient samples Of the 410 FH patients screened, five (1'2%), all of whom were Caucasian, were identified as heterozygous for FH E80K (Table I) and this finding was confirmed by DNA sequence analysis ( Fig. 4) . Their clinical and biochemical features are shown in Table 2 . Three had a family history of early onset coronary heart disease, and four had either tendon xanthomata, corneal arcus or both. Only one individual, CM, had a personal history of coronary heart disease.
Analysis of microsatellite marker
The analysis of microsatellite markers relies upon gel electrophoresis: marker D 19S394 is a tetranucleotide rather than a dinucleotide repeat and is less susceptible to shadow or stutter bands typical when genotyping these categories of repeat length polymorphisms.P' Sizing of PCR products using the Applied Biosystems methodology with internal size standards determines alleles as product sizes expressed as a fraction, i.e., as a mobility unit. These must be rounded up or down, and for a tetranucleotide repeat, a maximal difference of I· 5 mobility units was found to be appropriate. The between-run reproducibility of the sizing of the microsatellite alleles was 100% and duplicate running of samples in adjacent tracks further strengthened the recognition of identity of allele size. D 19S394 is a highly heterozygous marker with a heterozygosity value of 0·9. Sixteen allele sizes have been observed, varying from the smallest of 215 nucleotides (nt) to the largest of 275 nt. Out of 17 individuals heterozygous for FH E80K, 16 had a variable number of tandem repeat (VNTR) size of 239 nt. These 17 probands included the five outlined in this paper and 12 others, also Caucasians from the UK, described previously."
Family studies DNA was isolated from the family members of individual LF and analysed for the presence of FH E80K. Both the proband II-I and her brother, 11-4, have inherited the mutation from their father, 1-2, who died from a myocardial infarction age 54. In turn, the mutation has been transmitted to two of her children, III-I and II1-3 ( Fig. 5) . Inspection of the pedigree shows the 239 nt VNTR allele, tracking with the FH E80K mutation. The clinical and biochemical features offamily members studied are outlined in Table 3 . family, the haplotype carrying the E80K mutation was unambiguously identified as Sfa NI+/Sma i -tsi« I+/Hinc II-/Ava 1I+/M.I'p 1+. The genotypes of the four remaining probands were consistent with the E80K mutation being associated with this haplotype.
Haplotype analysis Following genotype analysis of the six LDL receptor genotypes in individuals from the LF
Response to lipid-lowering medication All five pro bands were receiving both dietary advice and lipid-lowering medication. Table 4 shows their lipid levels on diet alone and then after at least 3 months' medication when lipid levels had stabilized. Total serum cholesterol fell from 11·5 to 7·8 mmol/L, a mean total fall of 3·7mmol/L (95% CI 0·0, 7·3; P<0·05). Serum concentrations of LDL cholesterol fell from 7·6 to 5-4mmol/L, a mean fall of 2·2mmol/L (95% CI 0,0, 4·5; P<0·05).
DISCUSSION
In this report, we have described a rapid and sensitive method for detecting the FH E80K mutation. It is much simpler than previously used techniques and ideally suited for use in studies relating to the prevalence of the mutation in different populations or in following its inheritance in affected families. It is particularly suitable for use in the microtitre array diagonal gel electrophoresis system (MADGE) whereby between 1000 and 2000 samples can be screened in a single batch." The method will. however, detect any other substitution or deletion affecting the first two nucleotides of codon 80. that abolish the Taq I restriction site. Thus, samples testing positive by the restriction assay should be confirmed by sequencing. Using the method described. we identified five individuals who were heterozygous for FH E80K; one from Southampton; one from Edinburgh; and three from Newport. This represents 1·2% of the 410 individuals, with a clinical diagnosis of FH, who were studied. This frequency is of similar magnitude to the 2·5% (5/200) of patients with a diagnosis of FH attending lipid clinics in the London area, but much lower than the 14·2% (11/77) of FH patients attending a lipid clinic in Manchcster.i Serum cholesterol levels ranged from 8·8 to 15·6 mmol/L with a mean value of 11.5 rnmol/L, which are typical of values observed in FH heterozygotes." All of the probands were receiving lipidlowering therapy, and all responded to their medication, with mean falls of 29% in both total and LDL cholesterol. Although they were not receiving a standard drug regimen, these responses were nevertheless in keeping with those previously reported for FH heterozygotes receiving HMG CoA reductase inhibitors of one form or another. 28 • 29 The E80K substitution occurs in the second of the cysteine-rich repeated sequences at the Sim~Simvastatin; Chol = cholestyraminc; Beza = bezafibrate; NA = data not available.
N-terminal end of LDL receptor.' It results in the precursor form of the mutant protein being processed more slowly than normal with approximately 50% being degraded before it reaches the mature form. Furthermore, receptors containing the mutant protein bind P-VLDL normally, but exhibit abnormal binding of LDL. 30 Those receptor mutations whose protein product retains the ability to bind and internalize P-VLDL but not LDL, tend to have lower circulating LDL cholesterol concentrations and less severe clinical seq uelae. 2.3 Although the numbers are small, the findings of the present report support this thesis. Tendon xanthomata were observed in only 40% (2/5) of the probands, all of whom were aged over 36 years. In FH heterozygotes of this age range, xanthomata would have been expected in at least 80%. 27 In addition, neither xanthomata nor corneal arcus were observed in any of the living members of the LF family nor in her father who died of an MI at age 54. It has been suggested that stricter criteria should be applied in making a definite diagnosis of heterozygous FH, and that as well as hypercholesterolaemia in the proband, either the proband or first-degree relative must have xanthomata." Applying these criteria to our sample population, would have led to three probands and the entire LF family not being classified as clinically FH. If the criteria were applied on a wide basis, particularly in screening programmes, it would lead to an ascertainment bias, with an underestimate of the frequency of FH E80K. Highly polymorphic micro satellite loci represent a new and powerful tool in identity-bydescent.V and linkage disequilibrium studies.P and their use has become widely used in genome scanning." Although dinucleotide markers are more abundant in the human genome than tetranucleotide repeats, the latter are distinguished from the (CA)n markers by being easier to genotype as they show less laddering artefact when typed by PCR. 24 This laddering effect, seen as 'shadow bands', is thought to be due to a template-switching phenomenon, or to slippedstrand mispairing during the PCR. Four bp stutters on tetranucleotide gels do not occur as frequently, and if they do, they have a much lower intensity, and so do not interfere in the identification of the specific amplification product.
To date, the E80K mutation has only been reported in France," and England." However, although much mutation detection has taken place in laboratories throughout Europe studying the molecular genetics of FH, E80K has not been observed elsewhere. In this report we have observed it in individuals from southern England, Scotland and Wales, suggesting that it is distributed throughout Britain. With two exceptions, all of the individuals with the E80K mutation from various parts of Britain share the same sized allele of 239 nt. The likelihood of this happening by chance would be of the order of O'I to the power of 16, assuming an approximate population frequency of D 19S394 size allele 239 nt of 0·1 (L Haddad and INM Day, personal communication). This strongly suggests that the E80K mutation is identical-bydescent in the 16 of the 17 probands identified in this report and points to an early mutational event, now widespread, in the British population. This hypothesis is supported by the finding that the haplotype associated with the E80K mutation, namely Sfa NI + /Sma r-[Stu 1+/ Hinc 11-/Ava II + /Msp 1+, is consistent with that previously described elsewhere in the British Isles.' The one case identified where the mutational chromosome does not display the 239 nt allele size may be explained by one of several causes: a recombination event between the mutation and the polymorphic site; a replication slippage (slipped-strand mispairing) of the microsatellite during meiosis; or a second de novo occurrence of the E80K mutation. However, the LDL receptor RFLP genotypes of this individual were consistent with the E80K mutation being associated with the above intragenic haplotype, although the haplotype could not be deduced unambiguously and therefore exclude the possibility of recurrent E80K mutation. This observation would favour a recombination event between the microsatellite locus and the E80K mutation. Accurate dating of the main E80K mutation may be determined by studying recombination between flanking microsatellites and the LDLR gene. Future studies using a much larger number of E80K probands and using more detailed, i.e. more informative, intragenic RFLP haplotyping to examine the possibility of E80K being a recurrent mutation, may enable a more accurate estimate. However, assuming one recombination out of seventeen meioses for D 19S394 (approximately 250 kb, assumed 0·25 cM notwithstanding incongruities between physical and genetic distances),'? we estimate the E80K mutation to be 500-1000 years old, consistent with an apparent population distribution spanning the UK, but not widely prevalent in Europe.
